经典猪瘟病毒E2亚单位疫苗在韩国济州岛饲养和保育动物中的安全性和免疫原性的现场评价

IF 2.1 Q4 IMMUNOLOGY
Guehwan Jang, Eun-Joo Kim, Seong-Cheol Cho, Sung-Up Moon, Byeong Soo Kim, Jinhee Kim, Kyoung Ju Jeong, Kyungok Song, Seong Hwan Mun, Won-Myoung Kang, Jonghoo Lee, Changnam Park, Hyoung-Seok Yang, Changhee Lee
{"title":"经典猪瘟病毒E2亚单位疫苗在韩国济州岛饲养和保育动物中的安全性和免疫原性的现场评价","authors":"Guehwan Jang,&nbsp;Eun-Joo Kim,&nbsp;Seong-Cheol Cho,&nbsp;Sung-Up Moon,&nbsp;Byeong Soo Kim,&nbsp;Jinhee Kim,&nbsp;Kyoung Ju Jeong,&nbsp;Kyungok Song,&nbsp;Seong Hwan Mun,&nbsp;Won-Myoung Kang,&nbsp;Jonghoo Lee,&nbsp;Changnam Park,&nbsp;Hyoung-Seok Yang,&nbsp;Changhee Lee","doi":"10.7774/cevr.2022.11.3.264","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Classical swine fever (CSF) reemerged on CSF-free Jeju Island where vaccination is not practiced by the unintentional injection of a live attenuated vaccine (modified live attenuated vaccines-low-virulence Miyagi [MLV-LOM]) in 2014. Since the Jeju provincial authority is considering adopting a voluntary immunization policy using a CSF-E2 subunit vaccine to combat LOM-derived CSF endemic, this study aimed to evaluate in Jeju herds.</p><p><strong>Materials and methods: </strong>Two vaccination trials using the Bayovac CSF-E2 vaccine licensed for use in South Korea assessed the safety and humoral immunity of the CSF-E2 vaccine in breeding (trial 1) and nursery animals (trial 2) under farm application conditions.</p><p><strong>Results: </strong>Neither local nor systemic (including reproductive) adverse effects were objectively observed in pregnant sows and young piglets following a respective vaccination regime at pregnancy or weaning, respectively. Trial 1 showed that sows immunized with the CSF-E2 vaccine possessed high and consistent E2-specific and neutralizing antibody levels. The CSF-E2 vaccine-immunized pregnant sows subsequently conferred appropriate and steady passive immunity to their offspring. In trial 2, a double immunization scheme of the CSF-E2 vaccine in piglets at 40 and 60 days of age could elicit a consistent and long-lasting adequate antibody response. Additionally, the two trials detected no E<sup>rns</sup>-specific antibody responses, indicating that CSF-E2 vaccine can differentiate infected from vaccinated animals (DIVA).</p><p><strong>Conclusion: </strong>Our trial data collectively provide invaluable information on applying the CSF-E2 subunit vaccine to circumvent the possible drawbacks associated with the MLV-LOM concerning the safety, efficacy, and DIVA, in the LOM-endemic field farms and contribute to advanced CSF eradication on Jeju Island.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/b9/cevr-11-264.PMC9691865.pdf","citationCount":"0","resultStr":"{\"title\":\"Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea.\",\"authors\":\"Guehwan Jang,&nbsp;Eun-Joo Kim,&nbsp;Seong-Cheol Cho,&nbsp;Sung-Up Moon,&nbsp;Byeong Soo Kim,&nbsp;Jinhee Kim,&nbsp;Kyoung Ju Jeong,&nbsp;Kyungok Song,&nbsp;Seong Hwan Mun,&nbsp;Won-Myoung Kang,&nbsp;Jonghoo Lee,&nbsp;Changnam Park,&nbsp;Hyoung-Seok Yang,&nbsp;Changhee Lee\",\"doi\":\"10.7774/cevr.2022.11.3.264\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Classical swine fever (CSF) reemerged on CSF-free Jeju Island where vaccination is not practiced by the unintentional injection of a live attenuated vaccine (modified live attenuated vaccines-low-virulence Miyagi [MLV-LOM]) in 2014. Since the Jeju provincial authority is considering adopting a voluntary immunization policy using a CSF-E2 subunit vaccine to combat LOM-derived CSF endemic, this study aimed to evaluate in Jeju herds.</p><p><strong>Materials and methods: </strong>Two vaccination trials using the Bayovac CSF-E2 vaccine licensed for use in South Korea assessed the safety and humoral immunity of the CSF-E2 vaccine in breeding (trial 1) and nursery animals (trial 2) under farm application conditions.</p><p><strong>Results: </strong>Neither local nor systemic (including reproductive) adverse effects were objectively observed in pregnant sows and young piglets following a respective vaccination regime at pregnancy or weaning, respectively. Trial 1 showed that sows immunized with the CSF-E2 vaccine possessed high and consistent E2-specific and neutralizing antibody levels. The CSF-E2 vaccine-immunized pregnant sows subsequently conferred appropriate and steady passive immunity to their offspring. In trial 2, a double immunization scheme of the CSF-E2 vaccine in piglets at 40 and 60 days of age could elicit a consistent and long-lasting adequate antibody response. Additionally, the two trials detected no E<sup>rns</sup>-specific antibody responses, indicating that CSF-E2 vaccine can differentiate infected from vaccinated animals (DIVA).</p><p><strong>Conclusion: </strong>Our trial data collectively provide invaluable information on applying the CSF-E2 subunit vaccine to circumvent the possible drawbacks associated with the MLV-LOM concerning the safety, efficacy, and DIVA, in the LOM-endemic field farms and contribute to advanced CSF eradication on Jeju Island.</p>\",\"PeriodicalId\":51768,\"journal\":{\"name\":\"Clinical and Experimental Vaccine Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/b9/cevr-11-264.PMC9691865.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7774/cevr.2022.11.3.264\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2022.11.3.264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:2014年,由于不小心注射减毒活疫苗(改良型低毒宫城活疫苗[MLV-LOM]),在没有猪瘟的济州岛重新出现了经典猪瘟(CSF)。由于济州道当局正在考虑采用CSF- e2亚单位疫苗的自愿免疫政策来对抗lm来源的CSF地方性疾病,本研究旨在对济州岛牛群进行评估。材料和方法:两项使用韩国许可使用的Bayovac CSF-E2疫苗的疫苗接种试验评估了CSF-E2疫苗在农场应用条件下在育种(试验1)和保育动物(试验2)中的安全性和体液免疫。结果:在妊娠期或断奶期分别接种疫苗的怀孕母猪和幼仔猪中,均未客观观察到局部或全身(包括生殖)不良反应。试验1表明,接种CSF-E2疫苗的母猪具有高且一致的e2特异性和中和抗体水平。接种CSF-E2疫苗的妊娠母猪随后赋予其后代适当和稳定的被动免疫。在试验2中,在40日龄和60日龄的仔猪中接种CSF-E2疫苗的双重免疫方案可以引起一致和持久的充分抗体反应。此外,两项试验均未检测到nns特异性抗体反应,表明CSF-E2疫苗可以区分感染动物与接种动物(DIVA)。结论:我们的试验数据为应用CSF- e2亚单位疫苗规避MLV-LOM在安全性、有效性和DIVA方面可能存在的缺陷提供了宝贵的信息,并为济州岛的晚期CSF根除做出了贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea.

Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea.

Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea.

Field evaluation of the safety and immunogenicity of a classical swine fever virus E2 subunit vaccine in breeding and nursery animals on Jeju Island, South Korea.

Purpose: Classical swine fever (CSF) reemerged on CSF-free Jeju Island where vaccination is not practiced by the unintentional injection of a live attenuated vaccine (modified live attenuated vaccines-low-virulence Miyagi [MLV-LOM]) in 2014. Since the Jeju provincial authority is considering adopting a voluntary immunization policy using a CSF-E2 subunit vaccine to combat LOM-derived CSF endemic, this study aimed to evaluate in Jeju herds.

Materials and methods: Two vaccination trials using the Bayovac CSF-E2 vaccine licensed for use in South Korea assessed the safety and humoral immunity of the CSF-E2 vaccine in breeding (trial 1) and nursery animals (trial 2) under farm application conditions.

Results: Neither local nor systemic (including reproductive) adverse effects were objectively observed in pregnant sows and young piglets following a respective vaccination regime at pregnancy or weaning, respectively. Trial 1 showed that sows immunized with the CSF-E2 vaccine possessed high and consistent E2-specific and neutralizing antibody levels. The CSF-E2 vaccine-immunized pregnant sows subsequently conferred appropriate and steady passive immunity to their offspring. In trial 2, a double immunization scheme of the CSF-E2 vaccine in piglets at 40 and 60 days of age could elicit a consistent and long-lasting adequate antibody response. Additionally, the two trials detected no Erns-specific antibody responses, indicating that CSF-E2 vaccine can differentiate infected from vaccinated animals (DIVA).

Conclusion: Our trial data collectively provide invaluable information on applying the CSF-E2 subunit vaccine to circumvent the possible drawbacks associated with the MLV-LOM concerning the safety, efficacy, and DIVA, in the LOM-endemic field farms and contribute to advanced CSF eradication on Jeju Island.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信